The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial.
 
Lisa Zimmer
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi; Sun Pharma
 
Angela Krackhardt
Honoraria - Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Novartis; Pierre Fabre
Research Funding - Vaccibody
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Gilead Sciences; Janssen; Novartis
 
Erwin S. Schultz
Honoraria - UCB
 
Daniela Goeppner
Consulting or Advisory Role - Bristol-Myers Squibb; Pierre Fabre; Sanofi
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pierre Fabre; Sanofi
 
Chalid Assaf
Consulting or Advisory Role - 4SC; Helsinn Healthcare; Kyowa Kirin; Novartis; Recordati; Roche; Sanofi; Takeda
 
Dietrich Trebing
No Relationships to Disclose
 
Elisabeth Livingstone
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Medac; Novartis; Sanofi; Sun Pharma; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Medac; Pierre Fabre; Sun Pharma
 
Dirk Schadendorf
Honoraria - 4SC; Array BioPharma; Bristol-Myers Squibb; Immunocore; InflarxGmbH; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi/Regeneron; Sun Pharma; Ultimovacs
Consulting or Advisory Role - 4SC; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; NEKTAR; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron